Rex A. Parker
University of Kansas(US)The University of Kansas Health System(US)Bristol-Myers Squibb (Sweden)(SE)
Publications by Year
Research Areas
Peroxisome Proliferator-Activated Receptors, Pancreatic and Hepatic Oncology Research, Lipoproteins and Cardiovascular Health, Diabetes Treatment and Management, Peptidase Inhibition and Analysis
Most-Cited Works
- → Treatment of diabetes and atherosclerosis by inhibiting fatty-acid-binding protein aP2(2007)728 cited
- → Lack of macrophage fatty-acid–binding protein aP2 protects mice deficient in apolipoprotein E against atherosclerosis(2001)689 cited
- → Discovery and Preclinical Profile of Saxagliptin (BMS-477118): A Highly Potent, Long-Acting, Orally Active Dipeptidyl Peptidase IV Inhibitor for the Treatment of Type 2 Diabetes(2005)619 cited
- → Adipocyte/macrophage fatty acid binding proteins control integrated metabolic responses in obesity and diabetes(2005)486 cited
- → Hypocholesterolemic activity of synthetic and natural tocotrienols.(1992)295 cited
- → Dissection of the Endogenous Cellular Pathways of PCSK9-induced Low Density Lipoprotein Receptor Degradation(2009)265 cited